Business Description
Lyell Immunopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55083R1041
Share Class Description:
LYEL: Ordinary SharesDescription
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.65 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 1.52 | |||||
| Beneish M-Score | -67.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70 | |||||
| 3-Year EBITDA Growth Rate | 2.7 | |||||
| 3-Year EPS without NRI Growth Rate | 3.1 | |||||
| 3-Year FCF Growth Rate | 12.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.36 | |||||
| 9-Day RSI | 52.73 | |||||
| 14-Day RSI | 52.76 | |||||
| 6-1 Month Momentum % | 23.87 | |||||
| 12-1 Month Momentum % | -16.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.07 | |||||
| Quick Ratio | 16.07 | |||||
| Cash Ratio | 15.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | 0.97 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -190006.15 | |||||
| Net Margin % | -180486.15 | |||||
| FCF Margin % | -127984.62 | |||||
| ROE % | -31.65 | |||||
| ROA % | -27.94 | |||||
| ROIC % | -100.18 | |||||
| ROC (Joel Greenblatt) % | -159.68 | |||||
| ROCE % | -30.67 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2390 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 0.93 | |||||
| EV-to-EBIT | -0.5 | |||||
| EV-to-EBITDA | -0.55 | |||||
| EV-to-Revenue | 955.65 | |||||
| EV-to-Forward-Revenue | 700.3 | |||||
| EV-to-FCF | -0.52 | |||||
| Price-to-Net-Current-Asset-Value | 1.32 | |||||
| Price-to-Net-Cash | 1.34 | |||||
| Earnings Yield (Greenblatt) % | -200 | |||||
| FCF Yield % | -27.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LYEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyell Immunopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.13 | ||
| EPS (TTM) ($) | -0.93 | ||
| Beta | 0 | ||
| Volatility % | 102.72 | ||
| 14-Day RSI | 52.76 | ||
| 14-Day ATR ($) | 0.231697 | ||
| 20-Day SMA ($) | 2.2815 | ||
| 12-1 Month Momentum % | -16.88 | ||
| 52-Week Range ($) | 1.32 - 3.97 | ||
| Shares Outstanding (Mil) | 254.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lyell Immunopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lyell Immunopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lyell Immunopharma Inc Frequently Asked Questions
What is Lyell Immunopharma Inc(LYEL)'s stock price today?
The current price of LYEL is $2.39. The 52 week high of LYEL is $3.97 and 52 week low is $1.32.
When is next earnings date of Lyell Immunopharma Inc(LYEL)?
The next earnings date of Lyell Immunopharma Inc(LYEL) is 2024-05-03 Est..
Does Lyell Immunopharma Inc(LYEL) pay dividends? If so, how much?
Lyell Immunopharma Inc(LYEL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers